Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.
about
Animal Models of Uveal Melanoma: Methods, Applicability, and LimitationsCulturing Uveal Melanoma CellsUpcoming translational challenges for uveal melanomaNanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenografts.Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis).Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.Engineered cross-reacting nanobodies simplify comparative oncology between humans and dogs.Evaluation of the Effect of Everolimus on Retinal Pigment Epithelial Cells and Experimental Proliferative Vitreoretinopathy.Recent advances in uveal melanoma treatment.Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma.Selumetinib-based therapy in uveal melanoma patient-derived xenografts.
P2860
Q54605663-99597F59-6791-4E8E-93CE-24191AF1A27EQ54905161-1ABA1D75-BE3C-45A2-A6C4-419B5D5B4D0AQ54906090-A6018FA7-AA6D-4BAB-9D44-5E4C53BF00AEQ54906103-7249188F-89EB-43B6-B3DB-ED745D7B44E1Q54906192-504356E9-77AE-42BF-97A2-D258191DF58CQ54906428-EB944719-53CC-438F-A0DE-EE7506F0FC21Q54906429-AB9B00C5-7047-4238-BA21-696AB8E7BC23Q54906430-A1C51734-2FC4-407B-9C1B-EDDFD9DE6E3AQ54906431-7B43C4C7-8C76-432E-BF41-7ED850B513BCQ54936368-F0C0085F-A948-46CB-9C2C-5561913D2BDFQ54936373-BDC2F0A8-1BCA-4D92-90B6-89AD6A62E3A5
P1343
Q26745595-92D8BB1D-369F-47F8-AF05-AC16B0C594C6Q26750415-C4C400E8-8BF5-4FC2-98C3-14B4C9531060Q26778535-3667F62C-6DE4-411D-9479-4764F6BD719FQ36264686-8F0445B0-B299-45B7-A8B0-8E667656A340Q36549378-6A80B7C1-70E0-40E2-BB26-02AD587DF7E8Q37269087-BB062D84-A7F6-408D-B83E-C312F2B2F590Q38724341-AE99C562-066C-4D08-808B-AB7BFE013595Q41609825-9550674C-A6F4-4F1A-9656-F3DBC3565B55Q46280771-7B6E3994-0D9F-4B39-95D0-783B725D2249Q47356910-C64E575D-D44B-4F2E-AB48-C95E70A8ED70Q47571643-D70BF3CF-EE05-47FE-81BB-1B0AB20575CCQ50102285-E40272BC-BABA-4B38-8414-E9EF16AD8E33Q55091535-A9831990-67DC-442B-AC2B-A46CDA1B72A6
P2860
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Establishment of novel cell li ...... mTOR as a therapeutic target.
@en
type
label
Establishment of novel cell li ...... mTOR as a therapeutic target.
@en
prefLabel
Establishment of novel cell li ...... mTOR as a therapeutic target.
@en
P2093
P2860
P4510
P50
P1433
P1476
Establishment of novel cell li ...... mTOR as a therapeutic target.
@en
P2093
Amaury Dumont
André Nicolas
David Gentien
Didier Decaudin
Fariba Nemati
Guillaume Carita
Jacques Camonis
Laurence Desjardins
Nabil Amirouchene-Angelozzi
Nathalie Cassoux
P2860
P304
P356
10.1016/J.MOLONC.2014.06.004
P577
2014-06-13T00:00:00Z